Boston Scientific Lowers 2026 Guidance Due to Struggles in Key Businesses
Boston Scientific has cut its full-year 2026 sales and earnings per share (EPS) guidance for the second consecutive quarter, citing ongoing challenges in key business segments. CEO Mike Mahoney attributed the downward revision primarily to struggles within electrophysiology and Watchman units—two historically strong areas of growth that are now under pressure from competitive dynamics. The company now expects 2026 net sales growth between 5.5% and 6.5%, down from previous guidance of 7% to 8.5%. Adjusted EPS is also reduced, with a new range of $3.28 to $3.32 compared to the earlier forecast of $3.34 to $3.41. Watchman sales growth has slowed significantly in recent quarters due to declining standalone procedures and tougher year-over-year comparisons. In electrophysiology, Boston Scientific is facing increased competition from Medtronic, Johnson & Johnson, and Abbott—particularly in the pulsed field ablation (PFA) market—which had previously driven triple-digit portfolio growth. Despite maintaining a leadership position in PFA, its U.S. share has declined due to rising competitive pressures.
Tickers: $BSX